Industries > Pharma > Dermatological Drugs Market Forecast 2018-2028

Dermatological Drugs Market Forecast 2018-2028

Psoriasis, Skin Infection, Acne, Dermatitis, Others

PUBLISHED: 14 August 2018
PAGES: 333
PRODUCT CODE: PHA0325

Clear
WOOCS 2.2.1

The revenue of the dermatological drugs market in 2017 is estimated at $26.07bn and is expected to grow at a CAGR of 5.8% in the first half of the forecast period. Psoriasis drugs segment accounted for the largest share of the market in 2017, this segment accounted for 36% of the global dermatological drugs market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 333-page report you will receive 124 tables and 147 figures– all unavailable elsewhere.

The 333-page report provides clear detailed insight into the dermatological drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Dermatological drugs market forecasts from 2018-2028

• This report also breaks down the revenue forecast for the main submarkets:
• Psoriasis
• Skin Infections
• Acne
• Dermatitis

• Analysis of the Psoriasis drugs market. Revenue forecasts to 2028 are provided for the following drugs:
• Humira
• Stelara
• Enbrel
• Remicade
• Taltz
• Otezla
• Cosentyx

• Analysis of the Skin Infections drugs market. Revenue forecasts to 2028 are provided for the following drugs:
• Cubicin
• Zyvox
• Valtrex
• Canesten
• Lamisil
• Bactroban

• Analysis of the Acne drugs market. Revenue forecasts to 2028 are provided for the following drugs:
• Solodyn
• Epiduo
• Claravis
• Aczone
• Differin
• Abscorical/Epirus
• Ziana
• Doryx

• Analysis of the Dermatitis drugs market. Revenue forecasts to 2028 are provided for the following drugs:
• Bepanthen/Bepanthol
• Protopic
• Dermovate
• Elocon

• This report provides individual revenue forecasts to 2028 for these regional and national markets:
• North America: US & Canada
• Europe: Germany, France, UK, Italy, Spain, Rest of Europe
• Asia-Pacific: China, Japan, India, Rest of Asia-Pacific
• Latin America: Brazil, Mexico, Rest of Latin America
• Middle East & Africa (MEA): Saudi Arabia, South Africa, Rest of MEA

Dermatological Drugs Market Forecast 2018-2028

Each regional market is further segmented by indication: psoriasis, skin infection, acne, dermatitis and others.

• This report provides discussion on pipeline products in various stages of clinical trials and regulatory approval.

• Our study includes SWOT analysis and Porter’s Five Force analysis of the dermatological drugs market.

• Our study discusses the selected leading companies that are the major players in the dermatological drugs market:
• AbbVie
• Amgen
• Bayer AG
• Galderma (Nestle Skin Health S.A.)
• GlaxoSmithKline (GSK)
• Johnson & Johnson
• LEO Pharma
• Merck & Co, Inc.
• Novartis
• Pfizer

Our new report discusses issues and events affecting the dermatological drugs market:
• Highly fragmented and competitive market with significant variations in different geographic regions
• Changing political and regulatory landscape changing the prospects of future products and reimbursement opportunities
• Future paradigm-shifting pipeline products
• Patent expirations
• Launches of new drug categories
• Biosimilars approvals, Biosimilars interchangeability, Biosimilars guidance

Visiongain’s study is intended for anyone requiring commercial analyses for the dermatological drugs market. You find data, trends and predictions.

Buy our report today Dermatological Drugs Market: Psoriasis, Skin Infection, Acne, Dermatitis, Others.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Dermatological Drugs Market Forecast 2018-2028


Download sample pages

Complete the form below to download your free sample pages for Dermatological Drugs Market Forecast 2018-2028


Latest Pharma news

Visiongain Publishes Clinical Trial Supplies Market Report 2021-2031

Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.

11 October 2021

READ

Visiongain Publishes Drug Discovery Informatics Market Report 2021-2031

High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.

07 October 2021

READ

Visiongain Publishes Pharma Wholesale and Distribution Market Report 2021-2031

Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.

06 October 2021

READ

Visiongain Publishes Meningococcal Vaccines Market Report 2021-2031

Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations is expected to drive the global meningococcal vaccines market

05 October 2021

READ

Categories